[ad_1]
(Reuters) – A Chinese experimental coronavirus vaccine being developed by the Institute of Medical Biology of the Chinese Academy of Medical Sciences was shown to be safe in an early-stage clinical trial, the researchers said.
In a phase 1 trial of 191 healthy participants ages 18 to 59, vaccination with the group’s experimental injection showed no serious adverse reactions, their researchers said Tuesday in an article https://www.medrxiv.org/content /10.1101/2020.09 .27.20189548v1 released on medRxiv prepress server prior to peer review.
The most common adverse reactions reported by trial participants were mild pain, mild fatigue, and redness, itching, and swelling at the injection site.
The candidate also induced an immune response.
“All the data obtained in this trial support the safety and immunogenicity of this inactivated vaccine and are encouraging regarding further studies of its efficacy in the future,” the paper said.
China has inoculated hundreds of thousands of essential workers and other groups considered high-risk with other vaccines, even when clinical trials have not been fully completed, raising safety concerns among experts.
China has at least four experimental vaccines in the final stage of clinical trials.
(Reporting by Miyoung Kim; Editing by Robert Birsel)
